SEARCH:   Advanced

Blood, 28 May 2009, Vol. 113, No. 22, pp. 5476-5479. Prepublished online as a Blood First Edition Paper on March 18, 2009; DOI 10.1182/blood-2009-02-204800. This Article Full Text (PDF) Supplemental Table and Figures All Versions of this Article: blood-2009-02-204800v1 113/22/5476    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Loh, Y.-H. Articles by Daley, G. Q. Search for Related Content PubMed PubMed Citation Articles by Loh, Y.-H. Articles by Daley, G. Q. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 10, 2009 Accepted March 9, 2009 Generation of induced pluripotent stem cells from human blood Yuin-Han Loh, Suneet Agarwal, In-Hyun Park, Achia Urbach, Hongguang Huo, Garrett C. Heffner, Kitai Kim, Justine D. Miller, Kitwa Ng, and George Q. Daley* Department of Medicine, Division of Pediatric Hematology Oncology, Children's Hospital Boston, and Dana-Farber Cancer Institute, Boston, MA, United States Harvard Stem Cell Institute, Cambridge, MA, United States Howard Hughes Medical Institute, Boston, MA, United States Division of Hematology, Brigham and Women's Hospital, Boston, MA, United States * Corresponding author; email: george.daley{at}childrens.harvard.edu. Human dermal fibroblasts obtained by skin biopsy can be reprogrammed directly to pluripotency by the ectopic expression of defined transcription factors. Here, we describe the derivation of induced pluripotent stem (iPS) cells from CD34+ mobilized human peripheral blood cells using retroviral transduction of OCT4/ SOX2/ KLF4/ MYC. Blood derived human iPS cells are indistinguishable from human embryonic stem (ES) cells with respect to morphology, expression of surface antigens and pluripotency-associated transcription factors, DNA methylation status at pluripotent cell-specific genes, and the capacity to differentiate in vitro and in teratomas. The ability to reprogram cells from human blood will allow the generation of patient-specific stem cells for diseases in which the disease-causing somatic mutations are restricted to cells of the hematopoietic lineage. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Li, J. Zhou, G. Shi, Y. Ma, Y. Yang, J. Gu, H. Yu, S. Jin, Z. Wei, F. Chen, et al. Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells Hum. Mol. Genet., November 15, 2009; 18(22): 4340 - 4349. [Abstract] [Full Text] [PDF] D. S. Kaufman Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells Blood, October 22, 2009; 114(17): 3513 - 3523. [Abstract] [Full Text] [PDF] M. Okabe, M. Otsu, D. H. Ahn, T. Kobayashi, Y. Morita, Y. Wakiyama, M. Onodera, K. Eto, H. Ema, and H. Nakauchi Definitive proof for direct reprogramming of hematopoietic cells to pluripotency Blood, August 27, 2009; 114(9): 1764 - 1767. [Abstract] [Full Text] [PDF] C. L. Sweeney and H. L. Malech Functional neutrophils from human ES cells Blood, June 25, 2009; 113(26): 6503 - 6505. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020